Live Breaking News & Updates on Head Investor Relations Communications

Stay updated with breaking news from Head investor relations communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Santhera Publishes Agenda for its Annual General Meeting

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 28, 2024 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on June 18, 2024, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland. The invitation to the AGM with agenda items and explanations will be sent to registered shareholders by mail and can be viewed on Santhera’s website at https://www.santhera.com/share-bondholder-me ....

Switzerland General , United Kingdom , United States , Eva Kalias , European Medicines Agency , Members Of The Compensation Committee , Santhera Pharmaceuticals , Regulatory Agency , Drug Administration , Santhera Pharmaceuticals Holding , Head Investor Relations Communications , America To Catalyst Pharmaceuticals Inc , Annual General Meeting , Annual Report , Annual Financial Statements , Consolidated Financial Statements , Annual Result , Compensation Report , Executive Management , Financial Year , North America , Catalyst Pharmaceuticals , Head Investor Relations ,

Santhera Pharmaceuticals Holding AG: Santhera Publishes Agenda for its Annual General Meeting

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 28, 2024 - Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will ....

Switzerland General , Eva Kalias , Santhera Pharmaceuticals , Members Of The Compensation Committee , Santhera Pharmaceuticals Holding , Head Investor Relations Communications , Annual General Meeting , Annual Report , Annual Financial Statements , Consolidated Financial Statements , Annual Result , Compensation Report , Executive Management , Financial Year , Head Investor Relations , Ihr Portfolio ,

Santhera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2023

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 28, 2024 - Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2023 with fully audited results ....

Switzerland General , Eva Kalias , Head Investor Relations Communications , Santhera Pharmaceuticals Holding , Santhera Pharmaceuticals , Annual Report , General Meeting , Head Investor Relations , Ihr Portfolio ,

Santhera Publishes Annual Report 2023

Santhera Publishes Annual Report 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Switzerland General , United States , Eva Kalias , Regulatory Agency , America To Catalyst Pharmaceuticals Inc , Santhera Pharmaceuticals Holding , Santhera Pharmaceuticals , Head Investor Relations Communications , European Medicines Agency , Drug Administration , Publishes Annual Report , Annual Report , Annual General Meeting , North America , Catalyst Pharmaceuticals , Head Investor Relations ,

Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71.1 million) Cash flow from operating ....

United States , United Kingdom , Switzerland General , Shabir Hasham , Dario Eklund , Andrew Smith , Eva Kalias , Chiesi Farmaceutici , America To Catalyst Pharmaceuticals Inc , Life Science Alliance , National Institute For Health , Santhera Pharmaceuticals Holding , Catalyst Pharmaceuticals Inc , Exchange Regulation Ltd , Regulatory Agency , Santhera Pharmaceuticals Holding Ltd , Drug Administration , Chiesi Group , European Medicines Agency , European Union Summary Of Product Characteristics , Exchange Regulation , Catalyst Pharmaceuticals , Head Investor Relations Communications , China National Medical Products Administration , Santhera Pharmaceuticals , Announces Preliminary Unaudited ,